A study evaluating the safety, tolerability, and efficacy of GLPG5101 in adults with treatment-refractory active systemic lupus erythematosus

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504422-19-00

Acronym

GLPG5101-CL-104

Enrollment

Registered

2023-10-02

Start date

Unknown

Completion date

2024-02-22

Last updated

2024-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment-refractory active systemic lupus erythematosus

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Belgium, Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026